Thomas E. Timbie Sells 39,706 Shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI) Stock

Treace Medical Concepts, Inc. (NASDAQ:TMCIGet Rating) Director Thomas E. Timbie sold 39,706 shares of the stock in a transaction dated Friday, November 18th. The stock was sold at an average price of $22.70, for a total transaction of $901,326.20. Following the completion of the transaction, the director now owns 1,359,363 shares of the company’s stock, valued at $30,857,540.10. The sale was disclosed in a document filed with the SEC, which is available through this link.

Treace Medical Concepts Stock Down 0.4 %

Shares of TMCI stock opened at $22.14 on Thursday. Treace Medical Concepts, Inc. has a one year low of $12.48 and a one year high of $25.02. The company’s 50-day moving average is $22.75 and its 200 day moving average is $19.05. The company has a debt-to-equity ratio of 0.85, a current ratio of 5.66 and a quick ratio of 4.92.

Treace Medical Concepts (NASDAQ:TMCIGet Rating) last announced its quarterly earnings data on Tuesday, November 8th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.06. Treace Medical Concepts had a negative net margin of 35.87% and a negative return on equity of 51.67%. The company had revenue of $33.06 million for the quarter, compared to the consensus estimate of $30.10 million. Sell-side analysts forecast that Treace Medical Concepts, Inc. will post -0.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. BTIG Research increased their price target on shares of Treace Medical Concepts to $29.00 in a research note on Tuesday, November 15th. Morgan Stanley increased their price objective on shares of Treace Medical Concepts from $23.00 to $28.00 and gave the company an “overweight” rating in a research report on Tuesday, October 11th. Finally, Stifel Nicolaus increased their price objective on shares of Treace Medical Concepts from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Wednesday, September 21st.

Institutional Trading of Treace Medical Concepts

A number of institutional investors have recently made changes to their positions in TMCI. William Blair Investment Management LLC purchased a new stake in shares of Treace Medical Concepts during the 2nd quarter valued at about $11,740,000. Perceptive Advisors LLC boosted its holdings in shares of Treace Medical Concepts by 70.2% during the 3rd quarter. Perceptive Advisors LLC now owns 1,601,979 shares of the company’s stock valued at $35,356,000 after acquiring an additional 660,787 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of Treace Medical Concepts by 23.1% during the 3rd quarter. BlackRock Inc. now owns 2,268,911 shares of the company’s stock valued at $50,074,000 after acquiring an additional 425,350 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Treace Medical Concepts during the 3rd quarter valued at about $8,334,000. Finally, Kornitzer Capital Management Inc. KS purchased a new stake in shares of Treace Medical Concepts during the 2nd quarter valued at about $4,172,000. Hedge funds and other institutional investors own 40.96% of the company’s stock.

About Treace Medical Concepts

(Get Rating)

Treace Medical Concepts, Inc, an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement.

Read More

Insider Buying and Selling by Quarter for Treace Medical Concepts (NASDAQ:TMCI)

Receive News & Ratings for Treace Medical Concepts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Treace Medical Concepts and related companies with MarketBeat.com's FREE daily email newsletter.